Chapter 005

PART II: PHARMACOLOGY OF SPECIFIC DRUG GROUPS

Introduction to Autonomic Nervous System Drugs

Peter W. Abel and Michael T. Piascik

CITED REFERENCES

  1. Ahlquist RP: A study of adrenotropic receptors. Am J Physiol 153:586-600, 1948. PUBMED Abstract
  2. Andersson R: Cyclic AMP as a mediator of the relaxing action of papaverine, nitroglycerine, diazoxide, and hydralazine in intestinal and vascular smooth muscle. Acta Pharmacol Toxicol 32:321-336, 1973. PUBMED Abstract
  3. Axelrod J: Purification and properties of phenylethanolamine-N-methyl-transferase. J Biol Chem 237:1657-1660, 1962. PUBMED Abstract
  4. Berlan M, Montastruc JL, Lafontan M: Pharmacological prospects for α2-adrenoreceptor antagonist therapy. Trends Pharmacol Sci 13:277-282, 1992. PUBMED Abstract
  5. Berthelsen S, Pettinger WA: A functional basis for classification of α-adrenergic receptors. Life Sci 21:595-606, 1977. PUBMED Abstract
  6. Bevan JA: Some functional consequences of variation in adrenergic synaptic cleft width and on nerve density and distribution. Fed Proc 36:2439-2443, 1978. PUBMED Abstract
  7. Birnbaumer L: G proteins in signal transduction. Annu Rev Pharmacol Toxicol 30:675-705, 1990. PUBMED Abstract
  8. Burnstock G: Physiology and pathophysiology of purinergic neurotransmission. Physiol Rev 87:659-797, 2007. PUBMED Abstract
  9. Butcher FR: The role of calcium and cyclic nucleotides in α-amylase release from slices of rat parotid: studies with the divalent cation ionophore A-23187. Metabolism 24:409-418, 1975.
  10. Bylund DB, Eikenberg DC, Hieble JP, et al: International Union of Pharmacology nomenclature of adrenoceptors. Pharmacol Rev 46:121-136, 1994. PUBMED Abstract
  11. Cannon WB: Bodily changes in pain, hunger, fear, and rage, ed 2, New York, 1929, Appleton-Century.
  12. Caulfield MP, Birdsall JM: International union of pharmacology. XVII. Classification of muscarinic acetylcholine receptors. Pharmacol Rev 50:279-290, 1998. PUBMED Abstract
  13. Changeux J-P, Devillers-Thiery A, Cemouilli P: Acetylcholine receptor: an allosteric protein. Science 225:1335-1345, 1984. PUBMED Abstract
  14. DeLorenzo RJ, Freedman SD, Yohe WB, et al: Stimulation of Ca2-dependent neurotransmitter release and presynaptic nerve terminal protein phosphorylation by calmodulin and a calmodulin-like protein isolated from synaptic vesicles. Proc Natl Acad Sci U S A 76:1838-1842, 1979.
  15. Dionne RA, Goldstein DS, Wirdzek PJ: Effects of diazepam premedication and epinephrine-containing local anesthetic on cardiovascular and plasma catecholamine responses to oral surgery. Anesth Analg 63:640-646, 1984.
  16. Fitzgerald M: The course and termination of primary afferent fibres. In Wall P, Melzack R, editors: Textbook of pain, New York, 1984, Churchill Livingstone.
  17. Goldberg LI, Hsieh Y-Y, Resnekov L: Newer catecholamines for treatment of heart failure and shock: an update on dopamine and a first look at dobutamine. Prog Cardiovasc Dis 19:327-340, 1977. PUBMED Abstract
  18. Han C, Abel PW: Neuropeptide Y potentiates contraction and inhibits relaxation of rabbit coronary arteries. J Cardiovasc Pharmacol 9:675-681, 1987. PUBMED Abstract
  19. Hargreaves KM, Dionne RA, Mueller GP, et al: Naloxone, fentanyl, and diazepam modify plasma β-endorphin levels during surgery. Clin Pharmacol Ther 40:165-171, 1986. PUBMED Abstract
  20. Hubbard JI, Kwanbumbumpen S: Evidence for the vesicle hypothesis. J Physiol (London) 194:407-420, 1968. PUBMED Abstract
  21. Iversen LL: Catecholamine uptake processes. Br Med Bull 29:130-135, 1973. PUBMED Abstract
  22. Kobilka B: Adrenergic receptors as models for G protein-coupled receptors. Annu Rev Neurosci 15:87-114, 1992. PUBMED Abstract
  23. Limbird LE: α2-Adrenergic systems: models for exploring hormonal inhibition of adenylate cyclase. Trends Pharmacol Sci 4:135-138, 1983.
  24. Lukas RJ, Changeux J-P, le Novère N, et al: International Union of Pharmacology. XX. Current status of the nomenclature for nicotinic acetylcholine receptors and their subunits. Pharmacol Rev 51:379-401, 1999.
  25. Lundberg JM, Hedlund B, Bartfai T: Vasoactive intestinal polypeptide enhances muscarinic ligand binding in cat submandibular salivary gland. Nature 295:147-149, 1982.
  26. Matteoli M, DeCamilli P: Molecular mechanisms in neurotransmitter release. Curr Opin Neurobiol 1:91-97, 1991. PUBMED Abstract
  27. Mueller RA, Thoenen H, Axelrod J: Increase in tyrosine hydroxylase activity after reserpine administration. J Pharmacol Exp Ther 169:74-79, 1969.
  28. Piascik MT, Perez DM: α1-Adrenergic receptors: new insights and directions. J Pharmacol Exp Ther 298:403-410, 2001.
  29. Ralevic V, Burnstock G: Receptors for purines and pyrimidines. Pharmacol Rev 50:413-492, 1998. PUBMED Abstract
  30. Randich A, Maixner W: [D-Ala2]-methionine enkephalinamide reflexively induces antinociception by activating vagal afferents. Pharmacol Biochem Behav 21:441-448, 1984.
  31. Robitaille R, Adler EM, Charlton MP: Strategic location of calcium channels at transmitter release sites of frog neuromuscular synapses. Neuron 5:773-779, 1990.
  32. Schramm M, Selinger Z: The functions of cyclic AMP and calcium as alternative second messengers in parotid gland and pancreas. J Cyclic Nucleotide Res 1:181-192, 1975.
  33. Starke K: Regulation of noradrenaline release by presynaptic receptor systems. Rev Physiol Biochem Pharmacol 77:1-24, 1977. PUBMED Abstract
  34. Sutherland EW, Robison GA, Butcher RW: Some aspects of the biological role of adenosine 3',5'-monophosphate (cyclic AMP). Circulation 37:279-306, 1968.
  35. Todorov LD, Bjur RA, Westfall DP: Inhibitory and facilitatory effects of purines on transmitter release from sympathetic nerves. J Pharmacol Exp Ther 268:985-989, 1994. PUBMED Abstract
  36. Trimble WS, Linial M, Scheller RH: Cellular and molecular biology of the presynaptic nerve terminal. Annu Rev Neurosci 14:93-122, 1991. PUBMED Abstract
  37. Venter JC, Fraser CM: The structure of α- and β-adrenergic receptors. Trends Pharmacol Sci 4:256-258, 1983.
  38. Watson S, Arkinstall S: The G-protein linked receptor factsbook, London, 1994, Academic Press.
  39. Watson S, Girdlestone D: 1994 receptor and ion channel nomenclature supplement. Trends Pharmacol Sci 15(Suppl):1-51, 1994.
  40. Weiner N, Clotier G, Bjur R, et al: Modification of norepinephrine synthesis in intact tissue by drugs and during short-term adrenergic nerve stimulation. Pharmacol Rev 24:203-221, 1972. PUBMED Abstract
  41. Yuen PS, Garbers DL: Guanylyl cyclase-linked receptors. Annu Rev Neurosci 15:193-225, 1992. PUBMED Abstract
  42. Zhong H, Minneman KP: α1-Adrenoceptor subtypes. Eur J Pharmacol 375:261-276, 1999. PUBMED Abstract

GENERAL REFERENCES

  1. Alberts B, Johnson A, Lewis J, et al: Molecular biology of the cell, ed 4, New York, 2002, Garland Publishing.
  2. Cooper JR, Bloom FE, Roth RH: The biochemical basis of neuropharmacology, ed 8, New York, 2003, Oxford University Press.
  3. Kalsner S, editor: Trends in autonomic pharmacology, vol 2, Baltimore, 1982, Urban & Schwarzenberg.
  4. Kandel ER, Schwartz JH, Jessell TM: Principles of neural science, ed 4, New York, 2000, McGraw-Hill.
  5. Nestler EJ, Hyman SE, Malenka RC: Molecular neuropharmacology: a foundation for clinical neuroscience, New York, 2001, McGraw-Hill.
  6. Westfall TC, Westfall DP: Neurotransmission: the autonomic and somatic motor nervous systems. In Brunton LL, Lazo JS, Parker KL, editors: Goodman and Gilman’s the pharmacological basis of therapeutics, ed 11, New York, 2006, McGraw-Hill.